Loading
Pennant Group, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 May 2023.
Pennant Group, Inc.: what insiders have been doing
Pennant Group, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 15 insiders published 40 filings.
No insider bought on the market over the period, while 3 insiders filed 3 sales totalling €236k. At €143k, the sale published on 10 August 2026 by Guerisoli Brent is the largest of the period (0.012% of market cap).
Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,810 companies, median 19 filings), a count of 40 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 4 purchases and 17 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 947.7 m USD and net income at 29.6 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
207
Thresholds
n/a
Buy Volume
€598,752
4 ops. · all time
Sell Volume
€2M
17 ops. · all time
Who traded when
BuySaleBrent Guerisoli4 sales
Kirk Sterling Cheney2 sales
Stringfield JoAnne2 sales
Jason Paul Steik1 sale
Since the insiders bought
- +90.5%Entry US$12.00 · Close at T+365 US$22.86
- +38.0%Entry US$13.43 · Close at T+365 US$18.54
- +25.6%Entry US$10.91 · Close at T+365 US$13.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Pennant Group, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$46.83.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,222 of 24,148 companies
34.3
score / 100
Value36
Quality33
FCF yld2.5%
Earn yld2.0%
EV/EBITDA31.5x
ROE10%
Gross mgn14%
Net mgn3.1%
Debt/EBITDA7.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$40.82
Analyst consensus
6 analystsStrong buy
US$44.00Target US$46.83(+15%)US$49.00
Income statement
RevenueUS$947.7M
Gross profitUS$130.5M14% margin
EBITDAUS$60.8M6% margin
Net incomeUS$29.6M2.9% margin
Valuation
PER (trailing)44.9x
PER (forward)25.7x
P/Book4.0x
Beta1.25
Balance sheet & cash
Market capUS$1.4B
Total debtUS$453.2M
Free Cash FlowUS$36.3M
Debt / Equity123%
Profitability & ownership
ROE10.4%
ROA4.5%
% insiders5.0%
% institutions95.8%
Last declaration on 10 August 2026
Declarations207 total
1,393 shares@ US$38.5220.0038% mcap29.0% of flowCommon StockSEC:0001766400-26-000067:0
4,285 shares@ US$38.5220.012% mcap21.8% of flowCommon StockSEC:0001838360-26-000007:0
1,394 shares@ US$38.5220.0038% mcap50.0% of flowCommon StockSEC:0002078374-26-000003:0
1,393 shares@ US$38.52250.0038% mcap29.0% of flowCommonSEC144:0001959173-26-005719
4,285 shares@ US$38.52250.012% mcap21.8% of flowCommonSEC144:0001959173-26-005717
1,394 shares@ US$38.52250.0038% mcap50.0% of flowCommonSEC144:0001959173-26-005716
1,900 shares0Common StockSEC:0001183387-26-000002:0
1,900 shares0Common StockSEC:0001417555-26-000002:0
2,400 shares0Common StockSEC:0001375852-26-000002:0
1,900 shares0Common StockSEC:0001904610-26-000002:0
1,900 shares0Common StockSEC:0001437214-26-000003:0
1,900 shares0Common StockSEC:0001212067-26-000018:0
1,900 shares0Common StockSEC:0001470396-26-000014:0
6,248 shares@ US$4.540.0020% mcap3.8% of flowCommon StockSEC:0001838360-26-000005:0
3,159 shares@ US$41.5650.0094% mcap17.5% of flowCommonSEC144:0001959173-26-005190
6,249 shares@ US$4.540.0020% mcap3.8% of flowCommon StockSEC:0001838360-26-000003:0
3,165 shares@ US$40.510.0092% mcap17.1% of flowCommonSEC144:0001959173-26-005139
2,874 shares0Common StockSEC:0001766400-26-000041:0
11,260 shares0Common StockSEC:0001766400-26-000045:0
1,900 shares0Common StockSEC:0001766400-26-000049:0
1,900 shares0Common StockSEC:0001766400-26-000048:0
1,900 shares0Common StockSEC:0001766400-26-000040:0
1,900 shares0Common StockSEC:0001766400-26-000042:0
8,025 shares0Common StockSEC:0001766400-26-000039:0
11,214 shares0Common StockSEC:0001766400-26-000046:0
25 of 207 declarations
About Pennant Group, Inc.
The Pennant Group, Inc. (ticker: PNTG) is a U.S.-listed healthcare services company traded on NASDAQ in the United States. For French-speaking investors, Pennant is best understood as a specialized post-acute care platform built around independently operated subsidiaries. Its core business is organized into three main service lines: home health, hospice, and senior living communities. Based on the company’s investor materials and 2025 annual report, Pennant operates more than 120 home health and hospice agencies and more than 50 senior living communities across a broad multi-state footprint, including Arizona, California, Colorado, Idaho, Nevada, Oregon, Texas, Utah, Washington, Wisconsin, and other states in the American West and Midwest. The company’s headquarters are in Eagle, Idaho, underscoring its operational base in the western United States. Pennant was formed in 2019 as a growth platform in healthcare services, and its model is built on acquiring and developing local operating businesses while preserving a decentralized management structure. Each subsidiary is run with its own management team, employees, and assets, which is a notable feature of the group’s operating philosophy. From a competitive standpoint, Pennant is not a hospital operator or a diversified managed-care giant; rather, it competes in fragmented local markets where execution, care quality, census growth, and operational discipline are key value drivers. This makes the stock particularly relevant for investors seeking exposure to non-acute healthcare delivery, demographic tailwinds, and acquisition-driven growth. Recent company updates have reinforced that narrative. Pennant reported first-quarter 2026 results in early May 2026 and announced acquisitions of senior living communities in Arizona and Wisconsin, signaling continued expansion through M&A. In November 2025, the company also expanded its credit facility by $100 million to a total of $350 million, improving financial flexibility and providing additional capacity to support growth initiatives. Overall, PNTG is a NASDAQ-listed U.S. healthcare company with a focused footprint, a decentralized operating model, and a strategy centered on growth in home health, hospice, and senior living services.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
